Fumaryl Diketopiperazine Microparticles for Pulmonary Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods, particularly oral administration, face challenges with drug instability and inefficient absorption in the digestive tract, and pulmonary delivery faces difficulties in overcoming natural barriers and achieving uniform distribution of drugs.
Innovation Solution
Development of diketopiperazine microparticles with high drug adsorption capacity, specifically fumaryl diketopiperazine (FDKP) microparticles, which have a porous crystalline structure and high specific surface area, allowing for efficient pulmonary delivery of large doses of active agents like insulin and other peptides by forming a dry powder formulation that can be inhaled.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration is used for drug delivery, then ease of administration and patient compliance are improved, but drug instability and inefficient absorption in the digestive tract occur
Solution Approach 1:
The patent uses a carrier system (microparticles or nanoparticles) as an intermediary to protect the drug from degradation in the digestive tract. The carrier shields the unstable drug compound during oral administration, allowing it to reach the target site intact while maintaining ease of oral dosing.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the drug delivery system by formulating the drug in specialized carriers with controlled properties (size, surface characteristics, release profiles) to enhance stability and absorption while maintaining oral administration benefits.
2Productivity
If pulmonary delivery is used to overcome digestive tract limitations, then drug delivery efficiency is improved, but difficulty in overcoming natural barriers and achieving uniform distribution occurs
Solution Approach 1:
The patent divides the drug into discrete microparticle or nanoparticle units, each independently capable of navigating the respiratory tract barriers. This segmentation allows uniform distribution across the lung surface while simplifying the delivery mechanism to basic inhalation.
Solution Approach 2:
The patent transitions from systemic or gastrointestinal delivery to pulmonary delivery, utilizing the unique two-dimensional alveolar surface area of the lungs for rapid absorption. This dimensional change in delivery route provides efficient systemic access while avoiding digestive tract barriers.
3Quantity of substance
If large doses of drugs are delivered to achieve therapeutic effects, then treatment efficacy is improved, but coughing and potential loss of lung function occur
Solution Approach 1:
The patent employs porous microparticles or nanoparticles that provide high surface area to volume ratio, enabling large drug loading capacities within small particle volumes. This allows delivery of therapeutically effective doses without requiring large amounts of powder that would irritate the lungs.
Solution Approach 2:
The patent creates composite particle systems combining the drug with carrier materials that optimize both drug loading capacity and pulmonary compatibility. The composite structure enables high drug content while maintaining particle properties suitable for safe inhalation delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FDKP microparticles enable effective delivery of high drug content in smaller powder doses, improving treatment efficacy and patient compliance by efficiently overcoming natural barriers in the lungs and maintaining excellent aerodynamic performance.
Implementation Method 1
diketopiperazine microparticles having high capacity for drug adsorption
Data Source
AI summary
Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.